AI assistant
X4 Pharmaceuticals, Inc — Director's Dealing 2020
Aug 4, 2020
34355_dirs_2020-08-04_85332e07-a0f1-45c9-864a-44bd784b83c8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2020-08-03
Reporting Person: Ragan Paula (President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-03 | Common Stock | S | 2400 | $7.45 | Disposed | 208912 | Direct |
Footnotes
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.41 to $7.48, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Of the shares of common stock reported, 41,946 shares represent unvested restricted stock units.